THYROCARE558.00

Thyrocare Technologies Ltd.

· Pharma & Health
₹ CrorePeersLALPATHLABMETROPOLISVIJAYASUPRIYAVIYASHSTARSPARCYATHARTHMcap ₹8,882 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)105.4390.2380.8780.87
Receivable Days (DSO)27.7438.7632.5332.53
Payable Days (DPO)88.99147.75109.09105.96
Cash Conversion Cycle (days)44.18-18.764.317.44
Working Capital Turnover3.043.183.163.34
Asset Turnover0.890.991.111.11
Cash Conversion (CFO/Net Income)2.412.111.311.31
CFO/EBITDA1.221.010.810.81
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.